Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient

Epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer (NSCLC) patients benefit from EGFR tyrosine kinase inhibitors (TKIs), while some patients demonstrate a resistance to EGFR‐TKIs. In the case reported here, the NSCLC patient harboring an EGFR‐sensitive mutation and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Junyan, Sun, Dantong, Hou, Helei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471017/
https://www.ncbi.nlm.nih.gov/pubmed/32744377
http://dx.doi.org/10.1111/1759-7714.13583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471017/
https://www.ncbi.nlm.nih.gov/pubmed/32744377
http://dx.doi.org/10.1111/1759-7714.13583

Ejemplares similares